Find your next paid study

M.D. Anderson Cancer CenterNCT07700212

Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants w…

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.NCT05985655

Phase 2

Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)

This phase II trial tests whether 68Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) scan works to image cancer-associated fibroblasts (C…

Localized Pancreatic AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaStage 0 Pancreatic Cancer AJCC v8+2 more

Metastatic Pancreatic Adenocarcinoma

Mayo ClinicNCT05518903

Phase 2

Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)

The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (T…

Barbara Ann Karmanos Cancer InstituteNCT06576115

~$10 – $7,500

CholangiocarcinomaColorectal CancerNon-Small Cell Lung Cancer+1 more

Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)

This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients wit…

University of PennsylvaniaNCT07594067

Carcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of the Head and NeckEsophageal Squamous Cell Carcinoma+5 more

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the s…

Seagen, a wholly owned subsidiary of PfizerNCT05208762

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Pancreatic Adenocarcinoma+5 more

A Phase 1 Study of Bisaminoquinoline Derivative (TR-002) for Injection for Advanced Treatment-Refractory Solid Tumors

This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to…

University of California, DavisNCT07189195

Observational

"CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial"

The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with …

Malignant Head and Neck NeoplasmMalignant NeoplasmMetastatic Malignant Neoplasm in the Neck+45 more

Bile Duct CancerGall Bladder CancerBreast Cancer+6 more

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibiti…

University of FloridaNCT05000294

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe f…

Seagen, a wholly owned subsidiary of PfizerNCT04389632

Pancreatic Adenocarcinoma Non-resectable

A First-in-Human, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ACT Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine (ACT-IOP-003) Once Weekly or Twice Weekly Following First-Line Systemic Chemotherapy in Participants With Nonresectable Pancreatic Cancer

This study is being done to find out if delivering gemcitabine using the ACT-IOP-003 device directly to the area where the tumor is in the pancreas is safe and…

Continuity Biosciences, LLCNCT07481383

Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, Advanced+8 more

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamic…